CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues Mar 13, 2023 7:05am EDT
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland Mar 09, 2023 9:05am EST
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Feb 07, 2023 8:45am EST
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland Jan 12, 2023 8:45am EST
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event Jan 05, 2023 9:05am EST
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors Jan 03, 2023 12:00pm EST
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM) Dec 08, 2022 9:08am EST
CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event Dec 05, 2022 8:05am EST
CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price Nov 30, 2022 10:00pm EST
